Repository logo
 
Publication

Recombinant human erythropoietin therapy has beneffical cardio-renal effects on moderate stages of chronic renal failure in the rat

2009Conference object Open access
Simple item page
dc.contributor.authorGarrido, P.
dc.contributor.authorReis, F.
dc.contributor.authorCosta, Elísio
dc.contributor.authorParada, B.
dc.contributor.authorPiloto, N.
dc.contributor.authorSereno, J.
dc.contributor.authorTeixeira, A.
dc.contributor.authorPinto, R.
dc.contributor.authorFigueiredo, A.
dc.contributor.authorAlves, R.
dc.contributor.authorRocha-Pereira, P.
dc.contributor.authorBelo, L.
dc.contributor.authorSantos-Silva, A.
dc.contributor.authorTeixeira, F.
dc.date.accessioned2011-06-02T18:21:11Z
dc.date.available2011-06-02T18:21:11Z
dc.date.issued2009
dc.description.abstractThis study aimed to assess the cardio-renal effects of rhEPO therapy on an animal model of moderate chronic renal failure (CRF). Four groups (n =7) of male rat were evaluated during a 12-week follow up period: control; rhEPO: 50 IU/Kg/wk; CRF: two-stage 3/, nephrectomy; CRF+ rhEPO (start after the 3'd wk of surgery). Renal function, haematology and serum inflammation and redox status were assessed. rhEPO treatment was able to partially attenuate renal function markers, totally correct anaemia, also showing a proliferative and antioxidant action, due to increased serum TGF-13I and decreased 3-NT. In conclusion, rhEPO therapy might be recommended in moderate CRF stages in order to efficiently correct not only the underlying anaemia but also the deleterious cardio-renal effects, due to a proliferative and antioxidant renoprotective action.por
dc.identifier.citationCONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, 9th. Edinburgh, Scotland, United Kingdom, 12-15 July, 2009. In Proceedings of the European Association for Clinical Pharmacology and Therapeutics, p. 177 - 180por
dc.identifier.urihttp://hdl.handle.net/10400.14/4374
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherMedimond S.r.l. - Monduzzi Editore International Proceedings Divisionpor
dc.subjectModerate chronic renal failurepor
dc.subjectrhEPO therapypor
dc.subjectCardio-renal effectspor
dc.titleRecombinant human erythropoietin therapy has beneffical cardio-renal effects on moderate stages of chronic renal failure in the ratpor
dc.typeconference object
dspace.entity.typePublication
person.familyNameBelo
person.givenNameLuís
person.identifier.ciencia-idC319-EED1-E15D
person.identifier.orcid0000-0002-3941-6850
person.identifier.ridK-5878-2013
person.identifier.scopus-author-id6602879850
rcaap.rightsopenAccesspor
rcaap.typeconferenceObjectpor
relation.isAuthorOfPublication3654b7b5-7ad2-4f2f-9114-93dc094f8e9e
relation.isAuthorOfPublication.latestForDiscovery3654b7b5-7ad2-4f2f-9114-93dc094f8e9e

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2009_ICS_Costa_Elisio-dig31.pdf
Size:
125.81 KB
Format:
Adobe Portable Document Format
Download

Collections

FCSE - Documentos de Conferências / Conference Objects